The Hidden Challenge of Whooping Cough
Pertussis, commonly known as whooping cough, remains one of the world’s most persistent public health challenges. Despite decades of widespread childhood vaccination, this highly contagious respiratory disease, caused by the bacterium Bordetella pertussis, continues to cause significant morbidity and mortality, particularly in infants too young to be fully immunized. While our current generation of vaccines—specifically the acellular pertussis vaccines used in most developed nations—are excellent at preventing severe disease, they have a critical Achilles’ heel: they are not very good at preventing infection and transmission.
This means that even vaccinated individuals can become asymptomatic carriers of the bacteria, inadvertently spreading it to vulnerable populations. The scientific community has long recognized that to truly control pertussis, we need a vaccine that induces ‘mucosal immunity’—protection right where the bacteria first land: in the nose and throat. A recent Phase 2b trial published in The Lancet Microbe suggests we may finally have a candidate that can do just that.
